BioCryst Pharmaceuticals, Inc. has elected Sanj K. Patel to the Company’s Board of Directors. Mr. Patel has a proven track record of successfully developing and commercializing new products for rare diseases, and a deep interest in providing breakthrough treatments for these patients. He has leveraged his broad experience base in R&D, marketing and sales to grow and build companies that benefit patients and generate extraordinary value for all stakeholders.
Sanj Patel formed Synageva in 2008 and was its President & CEO through the company’s 8.4 billion USD acquisition by Alexion Pharmaceuticals in 2015.
“In recent years, I have gotten to know the BioCryst team, and we share a passion for developing and commercializing novel treatments for rare diseases. With results from two clinical trials for the prevention of hereditary angioedema attacks expected in 2015, it is an exciting time to join the BioCryst Board of Directors,” said Mr. Sanj Patel. “I look forward to working with the Board and the BioCryst Leadership Team as the Company advances toward commercialization of oral treatments for rare disease.”
(Source: BioCryst)
